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Introduction {#sec1}
============

Malaria remains a severe public health burden, causing an estimated 228 million cases and about 0.4 million deaths in 2018 ([@bib55]). Currently, artemisinin-based combination therapies (ACTs) are the first-line anti-malarial treatment recommended by [@bib55]. However, parasites resistant to artemisinin have emerged in Southeast Asia (SEA), leading to significant selection pressure on the partner drugs used in ACTs ([@bib2]). There is now evidence that resistance to piperaquine, the partner drug used in Cambodia, is indeed developing ([@bib3]; [@bib9]; [@bib15]; [@bib28]; [@bib53]). Phenotypically, resistant parasites exhibit an increased clearance half-life in patients and higher survival rates in the *in vitro*/*ex vivo* ring-stage survival assay (RSA) ([@bib2]; [@bib52]). Mutations in the kelch propeller domain (K13 mutations) are associated with artemisinin resistance in SEA ([@bib4]; [@bib43]) but not yet in Africa. While polymorphisms in the K13 gene are found in Africa, they have not led to resistance so far ([@bib24]; [@bib47]). However, there have been case reports on infected travelers returning from Africa responding poorly to ACTs, with some carrying resistance-associated K13 mutations, indicating an early sign of resistance development ([@bib40]; [@bib42]; [@bib45]; [@bib31]; [@bib39]; [@bib50]). Indeed, evidence now shows \>5% prevalence of artemisinin resistance associated K13 mutations in Rwanda, Guyana, and Papua New Guinea, but the clearance and efficacy of first-line treatment in the regions have not yet been affected ([@bib55]).

From the available data, it is clear that a single SNP in K13 cannot be solely responsible for the establishment and spread of artemisinin resistance in the field ([@bib1]; [@bib19]). Rather, it suggests a complex trait prevalent in SEA, with mutations in ferredoxin (fd), multidrug resistance protein 2 (mdr2), chloroquine resistance transporter (crt), and apicoplast ribosomal protein S10 (arps10), being linked with K13 mutations and resistance ([@bib35]). In fact, SEA has long been the hotbed for drug resistance development ([@bib14]). In addition to high drug pressure caused by extensive drug use and widespread counterfeit drugs in the area, earlier research also attributed this to the hypermutability or accelerated resistance to multiple drugs (ARMD) phenotype, whereby the parasite exhibited 1,000-fold higher rates of resistance to anti-malarial drugs compared with wild-type (WT) strains ([@bib8]). The phenotype was primarily linked to defects in DNA repair; most likely, DNA damage sensing ([@bib21]). Although the debate on the relationship between the ARMD phenotype and drug resistance development in SEA has continued, altered DNA repair has been linked to the resistance development in SEA ([@bib8]; [@bib29]).

As there are no equivalent alternatives to ACTs approved for clinical use, it is critical that we obtain a better understanding of all the factors that contribute to artemisinin resistance to facilitate better surveillance, containment, and prevention of artemisinin resistance. It has been shown that artesunate (a derivative of artemisinin) can induce DNA damage in trophozoite-stage malaria parasites after only 1 h of treatment and that DNA repair pathways are activated and able to repair damage caused by sub-lethal doses of artesunate ([@bib20]; [@bib21]).To explore the role of DNA damage repair in artemisinin resistance in the field, we adapted the previously developed CometChip, a high-throughput platform based on the well-established comet assay ([@bib41]; [@bib54]; [@bib16], [@bib17], [@bib18]; [@bib46]; [@bib51]), for the quantitative assessment of DNA damage in *P. falciparum* and analyzed lab-generated K13-resistant parasites and culture-adapted Cambodian clinical isolates from the Tracking Resistance to Artemisinin Collaboration, collected in Pailin, Cambodia, in 2011 ([@bib2]; [@bib5]). We further surveyed the available genome sequence data and identified a number of mutations in known DNA damage repair genes that are associated with the K13-resistant phenotype. Overall, we provided important insights on the important role of altered DNA repair in the establishment of artemisinin resistance in SEA. The information not only gives us better understanding of current artemisinin resistance but will also be valuable for surveillance as well as containment of artemisinin resistance.

Results {#sec2}
=======

Detection of Artesunate-Induced DNA Damage in Early and Late Stage *P. falciparum* Using Alkaline malariaCometChip {#sec2.1}
------------------------------------------------------------------------------------------------------------------

Previous work has suggested that artesunate induces DNA damage in the *P. falciparum* parasite via the formation of reactive oxygen species (ROS) ([@bib20]). Another study also showed that direct damage on purified plasmid DNA can be caused by a high concentration (non-physiologically relevant) of activated artemisinin *ex vivo* ([@bib56]). To obtain a more comprehensive understanding of artesunate-induced DNA damage, we first investigated the effect of artesunate, activated with ferrous heme or non-heme exogenous Fe^2+^, on purified DNA using more physiologically relevant concentrations. Our results showed that a lower concentration of activated artesunate did not induce single-strand breaks (SSBs) or double-strand breaks (DSBs) on purified DNA as compared with hydrogen peroxide ([Figure S1](#mmc1){ref-type="supplementary-material"}), which suggests that the effect of artesunate on cellular DNA inside the parasite involves further escalating of artesunate-relevant radicals and a (so far) poorly understood radical-related damaging mechanism. Since previous studies on artesunate-induced DNA damage used the classic comet assay ([@bib20]), this suggested that the damage could also be detected and assessed more easily using CometChip, a high-throughput platform previously developed for the study of DNA damage in mammalian cells based on the principle of the comet assay ([@bib54]; [@bib16], [@bib17], [@bib18]; [@bib46]; [@bib51]).

To adapt and optimize the CometChip platform for the study of malaria parasites, we first utilized hydrogen peroxide to induce DNA damage in the *P. falciparum* clone 3D7. In principle, as the amount of DNA damage increases (e.g., SSB, abasic site, etc.), DNA migration in electrophoresis under alkaline conditions increases ([@bib41]). Therefore, the percentage of DNA in the "comet" tail (% tail DNA), quantified as described in the [Supplemental Information](#app1){ref-type="fn"} and [Figure S2](#mmc1){ref-type="supplementary-material"}, was used to represent the level of DNA damage. Due to the relatively small genome size of malaria parasites, it is necessary to concentrate the parasites in the infected blood samples to obtain enough total DNA for reliable detection. For this, ring-stage parasites (0--18 h post-infection; h.p.i.) were treated with streptolysin O (SLO) as previously described ([@bib23]; [@bib26]) to obtain a highly enriched ring stage culture. These ring-stage parasites were loaded onto the CometChip, sealed with low-melting-point agarose (LMPA), and treated for 20 min with increasing concentrations of hydrogen peroxide followed by immediate alkaline lysis. An observable "comet" was already detected at the lowest (100 μM) hydrogen peroxide concentration and increased further as the concentration of hydrogen peroxide was raised ([Figure 1](#fig1){ref-type="fig"}A). The % tail DNA was quantified, and the results demonstrated a dose-dependent increase of % tail DNA in response to hydrogen peroxide in ring-stage parasites ([Figure 1](#fig1){ref-type="fig"}C). To study DNA damage in more mature parasites, schizont-stage parasites (estimated 30--48 h.p.i.) were concentrated using Percoll gradient centrifugation before ComentChip loading and hydrogen peroxide treatment. Similar to what had been observed with ring-stage parasites, hydrogen peroxide concentration-dependent increase of the % tail DNA was observed ([Figures 1](#fig1){ref-type="fig"}B and 1C). The data obtained with hydrogen peroxide suggested successful adaptation of the CometChip platform (malariaCometChip) in investigating the level of DNA damage in *P. falciparum* parasites.Figure 1Optimization of CometChip(A and B) Representative pictures of "comet" of ring and schizont-stage *P. falciparum* 3D7 after on-chip hydrogen peroxide (H~2~O~2~) treatment. Each green dot indicates a microwell in the CometChip. Each macrowell of the 96-well plate contains around \~300 of such microwells. The magnified view of the boxed area below shows the differentiation of head (between the green line and red line) and tail (between the red line and blue line) of an individual comet. This process would be automatically done by the algorithm as shown in the [Supplemental Information](#app1){ref-type="fn"}. Scale bars, 50 nm.(C) Quantification of "comet" after treatment. The y axis represents the percentage of DNA at the "comet" tail (%Tail DNA). On average, \~306 comets were analyzed per macrowell. Each experiment was done in technical triplicates, and data here were collected and are shown in biological triplicates. ^∗^p \< 0.05; ^∗∗^p \< 0.01, one-way analysis of variance (ANOVA). Dunnett's multiple comparison tests were performed between vehicle control (0 μM) and respective concentrations. All data are indicated as means ± SEM.

We then utilized the malariaCometChip to investigate the impact of artesunate on ring- and schizont-stage parasites. Enriched ring- and schizont-stage *P. falciparum* 3D7, *P. falciparum* laboratory strains Dd2 (denoted as "Dd2"), and K13 I543T mutant (derived from Dd2, denoted as "Dd2^I543T^") were investigated. Ring- and schizont-stage parasites were treated with different concentrations of artesunate, respectively, for 1 h *in vitro* before transfer onto the CometChip analkaline lysis (ring stage: 0--18 h.p.i.; schizont stage: 30--48 h.p.i.; [Figure 2](#fig2){ref-type="fig"}A). The time gap between artesunate treatment and on-chip alkaline lysis was limited to 5 min.Figure 2Artesunate-Induced DNA Damage in *P. falciparum* Lab Strains(A) Schematic illustration of artesunate treatment based on Streptolysin O (SLO) enrichment (ring stage) or Percoll gradient centrifugation (schizont stage).(B) Artesunate-induced DNA damage in *P. falciparum* 3D7, Dd2, and Dd2^I543T^. Ring-stage (upper panel) and schizont-stage (lower panel) *P. falciparum* parasites were treated with different concentrations of artesunate for 1 h and subjected to analysis on alkaline CometChip. On average, \~302 comets were analyzed per macrowell. Each experiment was done in technical triplicates, and data here were collected and are shown in biological triplicates or quadruplicates. ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; ^∗∗∗∗^p \< 0.0001, one-way ANOVA. Dunnett's multiple comparison tests were performed between vehicle control (0 μM) and respective concentrations. All data are indicated as means ± SEM.

Clear concentration-dependent DNA damage was observed in both ring- and schizont-stage 3D7 parasites ([Figure 2](#fig2){ref-type="fig"}B), demonstrating that artesunate-induced DNA damage can be detected and quantified on the malariaCometChip. Unlike in the case of the 3D7 strain, no artesunate-induced DNA damage can be observed in ring-stage Dd2 and Dd2^I543T^ ([Figure 2](#fig2){ref-type="fig"}B). In contrast, schizont-stage Dd2 exhibited a dose-dependent increase of the DNA damage, while Dd2^I543T^ showed a significantly lower amount of DNA damage ([Figure 2](#fig2){ref-type="fig"}B). The difference between the 3D7 and Dd2 strains and the difference between schizont-stage resistant and sensitive Dd2 strains indicate that an increased ability of parasites to deal with artesunate-induced DNA damage may enhance the survival chances of parasites and thus play an important role in resistance establishment.

DNA-Damage-Resistant Phenotype and Field Artemisinin Resistance {#sec2.2}
---------------------------------------------------------------

To explore this further, 7 culture-adapted clinical isolates from Pailin, Cambodia, were tested for artesunate-induced DNA damage at the schizont stage ([Figures 3](#fig3){ref-type="fig"}A and 3B). Resistant isolates KH004-003 (KH03), KH004-032 (KH32), and KH004-048 (KH48) showed no significant changes in DNA damage even at a 1,000-nM drug concentration, while the resistant strain KH004-014 (KH14) even showed a reduction in DNA damage at a higher concentration of artesunate treatment ([Figure 3](#fig3){ref-type="fig"}A). Sensitive isolates KH004-041 (KH41) and KH004-042 (KH42) showed significantly higher DNA damage at a 1,000-nM drug concentration, while surprisingly, the sensitive strain KH004-044 (KH44) showed a reduction or no significant change in DNA damage after artesunate treatment. The level of DNA damage at 1,000 nM artesunate treatment in different KH strains was found to be inversely correlated with their corresponding reported clinical clearance half-lives ([@bib36]) ([Figure 3](#fig3){ref-type="fig"}C). Based on clinical criteria, the resistant parasites are separated from sensitive ones at a clearance half-life \>5 h. With 21.7% normalized tail DNA as the separation criterion on the y axis, four zones were created and labeled counterclockwise as I, II, III, and IV. With zone II representing false-negative and zone IV representing false-positive results, 6 out of 7 strains tested located to the expected zones I and III, with the exception of KH44, which was located in zone II, indicating that resistant parasites as well as some sensitive parasites have an ability to deal more effectively with DNA damage induced by artesunate.Figure 3DNA Damage Resistance Phenotype in Cambodian Clinical Isolates(A) Artesunate-induced DNA damage in Cambodian KH004 clinical isolates. Schizont-stage KH isolates were treated with different concentrations of artesunate for 1 h. R represents artemisinin-resistant isolates, and S represents sensitive isolates. On average, \~316 comets were analyzed per macrowell. Each experiment was done in technical triplicates, and data here were collected and are shown in biological triplicates. ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001, two-way ANOVA. Comparisons were made between vehicle control and each concentration, and p values were adjusted after Šidák correction.(B) Information of the KH isolates used in this work. Information on mutations and clearance half-lives was provided by TRAC or extracted from its related study ([@bib36]). N/A, not applicable (e.g., data were not reported).(C) Correlation between DNA damage level at 1,000 nM artesunate and parasite clearance half-life in multiple clinical isolates. Linear regression was performed using Prism, and the dotted line indicates the linear fit curve. 5-hour clearance half-life is defined as the cutoff between artemisinin-resistant and sensitive parasites. The intersect between 5-hour clearance half-life and the linear fit curve is at %Tail DNA equal to 21.7%. Four zones were thus divided by 5 h of clearance half-life and 21.7% tail DNA and are labeled anti-clockwise as I, II, III, IV from upper left corner.(D) Methyl methane sulfonate (MMS)-induced DNA damage. Schizont-stage parasites *P. falciparum* 3D7, artemisinin-resistant KH004-003, and artemisinin-sensitive KH004-041 and KH004-044 were treated with different concentrations of MMS for 30 min. \~411 comets were analyzed per macrowell. Each experiment was done in technical triplicates, and data here were collected and are shown in biological triplicates. ^∗^p \< 0.05; ^∗∗^p \< 0.01, two-way ANOVA. Comparisons were made between vehicle control and each concentration, and p values were adjusted after Šidák correction. All data are indicated as means ± SEM.

To investigate whether this resistance to DNA damage is artesunate specific or represents a broader adaptation of the parasite to deal with DNA-damage-inducing agents, we treated KH44 and KH03 as well as 3D7 and KH41 with methyl methane sulfonate (MMS), which is known to methylate DNA bases and stall the replication forks, causing SSBs and DSBs ([@bib32]). After treatment as short as 30 min, clear MMS-induced DNA damage was observed in 3D7 and the sensitive KH41, but not in KH44 and the resistant KH03 parasites ([Figure 3](#fig3){ref-type="fig"}D), suggesting that the latter has greater intrinsic ability to deal with DNA damage instead of specifically dealing with an artesunate-induced one.

Taken together, our results suggest that some Cambodian field isolates are able to deal more effectively with DNA damage, possibly through a better repair mechanism. This ability to resist DNA damage is seen in all of the artemisinin-resistant parasites as well as a fraction of sensitive parasites. In other words, a subset of DNA-damage-resistant parasites may have developed artemisinin resistance, raising the question on whether the ability to better adapt to DNA damage is an important factor in developing resistance to artesunate.

Candidate Molecular Markers for Altered DNA Repair Capability {#sec2.3}
-------------------------------------------------------------

Previous work suggested that parasites defective in DNA damage repair, where repair accuracy is compromised due to increased repair speed, may contribute to higher levels of mutations and, by proxy, an increased rate in the development of drug resistance in SEA ([@bib34]; [@bib8]; [@bib29]). To understand the underlying genetic factors contributing to the lower level of DNA damage observed in KH44 and the other resistant parasites as compared with sensitive strains, we constructed a phylogenetic tree grouping samples from Pailin, Cambodia, 2011, including the KH samples used in this study, according to their genome-wide SNP similarity using available SNP data from the Pf3K database ([@bib5]; [@bib35]) ([Figure S4](#mmc1){ref-type="supplementary-material"}). Among the KH strains, KH41, KH42, and KH44 have WT *kelch13* and are considered artemisinin sensitive. KH41 and KH42, which showed DNA damage response to artesunate ([Figure 3](#fig3){ref-type="fig"}A), were closely related to each other and only distantly related to the resistant KH strains. However, KH44, which showed no DNA damage at high concentrations of artesunate treatment, clustered with resistant strains and was most closely related to the resistant strain KH14, which showed a similar decrease of comet tails upon artesunate treatment ([Figure 3](#fig3){ref-type="fig"}A).

To investigate further, mutations in known DNA repair genes ([Table S3](#mmc1){ref-type="supplementary-material"}) were compared in these clinical isolates. Considering KH44 as repair enhanced due to the low level of DNA damage it experienced after artesunate treatment ([Figure 3](#fig3){ref-type="fig"}A), seven mutations in six genes were found to be different between the five DNA damage repair enhanced KH strains and sensitive KH41 and KH42 ([Table 1](#tbl1){ref-type="table"}; [Table S1](#mmc1){ref-type="supplementary-material"}), including PF3D7_0710400 encoding DNA repair protein RAD14, which plays an important role in nucleotide excision repair and DNA damage recognition; PF3D7_100600 for IMP1-like protein involved in base excision repair; PF3D7_1106000 for RuvB-like helicase 2, which has ATP-dependent 5′-3′ DNA helicase activity; PF3D7_1368800 for DNA repair endonuclease XPF; PF3D7_1429900 for ADP-dependent DNA helicase RecQ; and PF3D7_1455300 for a conserved Plasmodium protein that plays a role in DNA mismatch repair. Among the seven genes, three of them---PF3D7_0710400, PF3D7_1106000, and PF3D7_1368800---were classified as essential according to previous work ([@bib57]), and PF3D7_1106000 was previously linked to resistance development ([@bib34], [@bib29]).Table 1List of Mutations Identified Different between DNA-Damage-Resistant and -Sensitive IsolatesGene IDPositionReferenceVariantTypeVariant TypeImpactAmino Acid ChangeProductPredict FunctionGene EssentialityPF3D7_0710400474979TA^∗^DELmissense_variantmoderate--DNA repair protein RAD14, putativenucleotide excision repair, DNA damage recognitionhigh475135AGSNPmissense_variantmoderateIle171MetPF3D7_1006000257175TAATCTT\
TCCCTTT\
CTTTTTC\
TTCTTCC\
AATAAT\
TTCTDELframeshift_variant&missense_varianthighLys164fsIMP1-like protein, putativeunknown functionlowPF3D7_1106000257027TCSNPmissense_variantmoderateAsn39AspRuvB-like helicase 2ATP-dependent 5′-3′ DNA helicase activityhighPF3D7_13688002731444TCGGTG\
GTCCAT\
TTTTTT\
CAACTT\
CCAGGT\
GGTCA\
TTTGTTT\
GAACTT\
CCAGAT\
GGTT^∗^DELframeshift_variant&missense_varianthighGlu1567fsDNA repair endonuclease XPF, putativeDNA repair, nuclease activityhighPF3D7_14299001178944TGATAAAGT,^∗^,TGATAATGDELframeshift_variant&missense_varianthighAsn725fsADP-dependent DNA helicase RecQATP-dependent 3′-5′ DNA helicase activitylowPF3D7_14553002260945TGSNPmissense_variantmoderateMet494Argconserved Plasmodium proteinmismatch repair, single-stranded DNA 5′-3′ exodeoxyribonuclease activity, flap endonuclease activitylow[^3]

For the subsequent analysis presented here, seven mutations in six genes were defined as "EnDNArep genotype," and their counterparts in WT K13 carrying parasites as "NormalDNArep genotype." Notably, WT Dd2, the ARMD strain that showed a lower level of DNA damage compared with KH41 at both the ring and schizont stages, possess three of the seven mutations in the EnDNArep genotype ([Table S1](#mmc1){ref-type="supplementary-material"}), suggesting a potential link between the EnDNArep genotype and ARMD phenotype.

EnDNArep Genotype and Development of Field Artemisinin Resistance {#sec2.4}
-----------------------------------------------------------------

To investigate whether the EnDNArep genotype is linked to K13 mutations and artemisinin resistance, linkage disequilibrium (LD) was assessed between K13 and each EnDNArep mutation using chi-square analysis, and the p values were plotted ([Figure 5](#fig5){ref-type="fig"}A). Heterozygotes (due to mixed infection) were excluded from the analysis. After Bonferroni correction on the p value, five out of seven mutations were found to be associated with K13 mutations in the SEA population with statistical significance, except for SNPs at PF3D7_0710400-474979 and PF3D7_1455300. Previous studies suggested a strong regional difference between parasite populations from the eastern and western Greater Mekong Sub-regions (e-GMS and w-GMS, respectively) in SEA ([@bib34], [@bib35]). LD was thus assessed between the EnDNArep genotype and K13 mutations after further dividing the SEA population into e-GMS and w-GMS groups, respectively ([Figure 4](#fig4){ref-type="fig"}). Consistent with previous observations, differences in gene associations were observed between the two regions. In e-GMS, where the KH strains analyzed in this study come from, six out of seven mutations were found to be highly associated with K13 mutations, except for SNPs at PF3D7_1455300 ([Figure 5](#fig5){ref-type="fig"}A). In contrast, only three out of seven mutations, including the SNPs at PF3D7_1106000 and the deletions in PF3D7_1006000 and PF3D7_1429900, were found to be associated with K13 mutations in w-GMS ([Figures 5](#fig5){ref-type="fig"}A and 5C).Figure 4Distribution of the EnDNArep Genotype in SEA and AfricaArea profile of K13 mutation prevalence (pie chart of WT, indicated in blue, and K13, indicated in magenta) and distribution of the EnDNArep genotype in parasites carrying WT K13 (WT; upper panel) and parasites carrying K13 mutations (K13; lower panel) in SEA and Africa. The x axis key and the bar chart key appear at the bottom of the figure. Areas belonging to e-GMS are indicated in orange squares. 111 cases representing Africa were mainly from Ilorin, Nigeria, and Kinshasa, Democratic Republic of Congo ([@bib5]).Figure 5Association of the EnDNArep Genotype with K13 Mutations in SEA(A) Chi-square analysis of gene association in different populations and sub-populations. SEA refers to the Southeast Asia population, which was further divided into e-GMS and w-GMS. The line was drawn at p = 0.00714, the y axis threshold after Bonferroni correction. Heterozygotes due to mixed infection were excluded from analysis.(B and C) Percentage of the EnDNArep genotype in the population from e-GMS (B) and w-GMS (C) along with the frequency of K13 mutations. Sisakhet and Ranong were excluded due to limited sample size (20 and 19 samples, respectively).(D and E) Distribution of the EnDNArep genotype in K13 C580Y parasites and parasites with other K13 mutations in e-GMS (D) and w-GMS (E). ^&^p \< 0.00714 (value after Bonferroni correction), Chi-square analysis between C580Y and other K13 mutations within the K13 population. The dotted line was drawn at 50%.

The distribution of the EnDNArep genotype in clinical isolates from different areas with different K13 mutation prevalence was analyzed. With the exception of SNPs at PF3D7_0710400-475135 and PF3D7_1455300, the frequency of the other mutations in the EnDNArep genotype decreased along with the frequency of K13 mutations across the areas in e-GMS ([Figure 5](#fig5){ref-type="fig"}B). In Pailin, where around 90% of the parasites carry K13 mutations---mostly C580Y---a high proportion of EnDNArep genotype was observed in the K13 parasites ([Figure 4](#fig4){ref-type="fig"}). In study sites with lower K13 mutation prevalence, the percentage of K13 parasites having EnDNArep genotype also becomes lower. For example, in Pursat, Cambodia, which has a lower prevalence of K13 mutations (77.32%) compared with Pailin, more than 60% of the K13 parasites have the mutations in the EnDNArep genotype except for PF3D7_1368800 (41.67%) ([Figure 5](#fig5){ref-type="fig"}). In Phuoc Long, where half of the population carry K13 mutations, only four out of seven mutations in the EnDNArep genotype were found to be over 50% in the K13 population ([Figure 5](#fig5){ref-type="fig"}). From a temporal perspective, most of the resistant parasites from Pailin, 2011, including the four KH-resistant strains investigated here, shared a similar EnDNArep genotype (average, around 80%), especially for PF3D7_1006000 (95.65%) and PF3D7_1455300 (100%) ([Figure S5](#mmc1){ref-type="supplementary-material"}). In 2012, as the frequency of K13 mutations remained high and the K13 C580Y mutation dominated in the area, the K13 parasites from Pailin further progressed, with an increased percentage of resistant parasites possessing the EnDNArep genotype (average, around 90%) ([Figure 5](#fig5){ref-type="fig"}), indicating an interplay between K13 mutations, especially C580Y, and the EnDNArep genotype in the K13-mediated artemisinin resistance.

The distribution of the EnDNArep genotype in WT parasites showed a broad similarity between areas in SEA but is clearly different in Africa. In places like Pailin and Pursat, where artemisinin resistance is prevalent, more than half of the WT parasites were found to possess the majority of the EnDNArep genotype ([Figure 5](#fig5){ref-type="fig"}). In Ramu, Bangledash, while geographically linked to Pailin but with no K13 mutation documented in 2012, four out of the seven mutations in the EnDNArep genotype were found in more than half of the WT parasites. In contrast, in the African samples, where only one K13 mutation was found in 111 cases representing Africa (mainly from Ilorin, Nigeria, and Kinshasa, Democratic Republic of Congo) ([@bib5]) and with clear geographic separation from SEA, only one out of the seven mutations in the EnDNArep genotype were found in more than half of the WT population.

A recent study showed that the K13 C580Y mutation gradually dominated other K13 mutations in the resistant population and is likely linked to higher fitness or transmission of the C580Y strains ([@bib22]). Temporal analysis in Pailin also showed an increased proportion of the EnDNArep genotype in the K13 population when C580Y became the only K13 mutation in the Pailin population from 2011 to 2012 ([Figure S5](#mmc1){ref-type="supplementary-material"}). To investigate whether the EnDNArep genotype is associated with C580Y, the C580Y carrying parasites in the two sub-populations were examined. The results showed a higher percentage of parasites carrying the EnDNArep genotype in the C580Y parasites, especially in e-GMS ([Figures 5](#fig5){ref-type="fig"}D and 5E). Analysis of LD between C580Y and other K13 mutations showed a close correlation between K13 C580Y mutation and the SNPs at PF3D7_0710400-475135 and PF3D7_1106000 and the deletions at PF3D7_0710400-474979 and PF3D7_1368800 in e-GMS ([Figure 5](#fig5){ref-type="fig"}D). In w-GMS, no significant association can be seen ([Figure 5](#fig5){ref-type="fig"}E).

Taken together, the data obtained here show a strong association between enhanced DNA repair and K13-mediated artemisinin resistance in SEA, especially e-GMS. Despite other factors, such as transmission pattern, human migration, and local health policies that may have contributed to such association, the EnDNArep genotype along with previously identified mutations ([@bib35]), may be part of the predisposing genetic background that is important for the initial establishment and subsequent spread of K13-mediated artemisinin resistance.

Discussion {#sec3}
==========

In this study, we investigated the ability of both lab-adapted parasites and clinical isolates to deal with artesunate-induced DNA damage using the optimized malariaCometChip ([@bib54]). The experimental data showing differences in DNA repair suggested that there are differences in the genetic background of these parasites that may provide them with an advantage for the development of artemisinin resistance in SEA. Here, we identified seven mutations, including nonsynonymous SNPs and deletions, in known DNA damage repair genes that may contribute to provide the right genetic background for the development of artemisinin resistance in SEA.

Our study has several important observations and implications. First, we observed a significantly improved ability of the schizont-stage, artemisinin-resistant parasite to deal with DNA damage due to short artesunate exposure. While the established phenotype of reduced artemisinin susceptibility is defined only in early ring-stage intra-erythrocytic parasites ([@bib7], [@bib13], [@bib48], [@bib52]), the improved ability of the resistant parasite to overcome DNA damage suggests an overall better ability to deal with artesunate-induced damage, regardless of stages. This may be important, as without an enhanced DNA repair, K13 mutant parasites that can survive exposure to artemisinin and sustained DNA damage at the ring stage could still fail to mature or produce viable progeny merozoites and thus be less likely to thrive. Therefore, enhanced DNA repair is more likely to be a fitness-enhancing trait for the resistant parasite. Second and most importantly, the enhanced DNA repair was also observed in the unique artemisinin-sensitive clinical isolate KH44, which, similar to resistant isolates, suffered no DNA damage from both artesunate and MMS treatment ([Figures 3](#fig3){ref-type="fig"}A and 3C). Of note, KH44 possesses SNP in *fd*, *mdr2*, and *crt*, the markers of the genetic background for contemporary artemisinin resistance development ([@bib35]). The existence of KH44 suggests that enhanced DNA repair could be a predisposing background for resistance to establish and subsequently spread in the field rather than something that developed afterward.

Analysis of KH44 and resistant isolates allowed us to identify seven mutations in known DNA repair genes that are linked to K13 mutations in the field. Except for the SNP in PF3D7_1106000, other mutations identified here have not been reported to be associated with artemisinin resistance. Top-ranked LD with K13 mutations was found in deletions in PF3D7_1006000 (IMP1-like protein) and PF3D7_1429900 (ADP-dependent DNA helicase RecQ) in both e- and w-GMS. Protein coded by PF3D7_1006000 was found to have mRNA binding activity at the trophozoite and schizont stages without information on protein structure. The deletion in PF3D7_1429900 is predicted to be in the intrinsically disordered region (IDR) of the protein. IDRs are thought to serve as flexible platforms for protein-protein interaction ([@bib44]), indicating a possible impact of the deletion on the protein function and the pathway involved. While these genes are predicted to be non-essential and have a high mutant fitness score *in vitro* ([@bib57]), this does not preclude them from providing essential functions under oxidative stress or at other stages of the life cycle. Presumably, having them mutated could help parasites rapidly adapt to the environment, which may partially explain the loss of resistance for some field isolates under long term *in vitro* culture (see [Table S2](#mmc1){ref-type="supplementary-material"}). The SNP in PF3D7_1455300 has a high frequency in SEA population, especially e-GMS, and thus appears to be not in LD with K13 mutations. However, it cannot be found in African populations. This SNP could be fixed in the population due to selection and become a signature for the SEA population.

The SNP in PF3D7_0710400-475135 and deletions found in PF3D7_0710400-474979 and PF3D7_1368800 were only significantly associated with K13 in e-GMS. The regional differences observed between e-GMS and w-GMS may be partially related to the hard selective sweep that took place in the area, whereby a resistant C580Y lineage, which originated from Pailin, spread to northeastern Thailand and southern Laos, outcompeted other parasites, and dominated the area ([@bib34], [@bib35]; [@bib58]; [@bib22]). It was suggested that this C580Y lineage may possess higher fitness or transmission than other resistant parasites, which thus led to the dominance. In the analysis of the Pailin K13 population, where the K13 C580Y mutation became the only K13 mutation type in 2012, the percentage of K13 parasites possessing the EnDNArep genotype further increased to around 90%, indicating a close relationship between the EnDNArep genotype and the dominating C580Y lineage ([Figure S5](#mmc1){ref-type="supplementary-material"}). The C580Y parasites from w-GMS were shown to have a different origin, explaining why these parasites have a different association pattern between the EnDNArep genotype and K13 mutations.

It is noteworthy that fully 50% of the DNA repair genes mutated preferentially in the resistant strains are genes that participate in homology-directed repair (HR), which is mostly error free. Resistant strains have mutations anticipated to reduce HR, which would shunt repair of DSBs to the error-guaranteed alternative nonhomologous end-joining pathway (Alt-NHEJ), which is expected to provide repair of DSBs in the absence of a homologous sequence ([@bib25]). For Alt-NHEJ, the joining of microhomology on either side of the breakpoint necessitates an associated deletion or addition, leading to potential mutations ([@bib25], [@bib33]). In addition, it is noteworthy that SSBs that are nearby on opposite strands can lead to DSBs. As the alkaline comet assay primarily detects SSBs ([@bib38]), the observation that resistant parasites have reduced levels of SSBs is consistent with a reduction in artemisinin-induced toxicity. Taken together, these parasites are expected to be simultaneously resistant to DNA damage-induced cytotoxicity while, at the same time, being prone to DNA damage-induced mutations.

We also observed the enhancement of DNA repair in the Dd2 parasite, albeit to a lower extent as compared with KH44 and the resistant parasite isolates ([Figure S3](#mmc1){ref-type="supplementary-material"}). Dd2 was previously linked to the ARMD phenotype but is fully susceptible to artemisinin and has a WT K13 locus. It also possesses three out of seven mutations from the EnDNArep genotype ([Table S1](#mmc1){ref-type="supplementary-material"}), indicating a potential link between the EnDNArep genotype and the accelerated development of drug resistance in general. As one of the ARMD strains, Dd2 was shown to have defects in sensing DNA damage and triggering DNA repair ([@bib21]) and, therefore, has a higher tolerance to damage, which led to higher mutation rates and accelerated development of resistance to multiple drugs ([@bib8], [@bib49]). Although there have been debates on the existence of the ARMD phenotype in Southeast Asia, and although the ARMD phenotype was previously linked to mismatch repair pathways ([@bib6], [@bib11], [@bib8]), both previous studies ([@bib29], [@bib34]) and evidence here have suggested potential links between mutations in DNA repair genes, accelerated rates of resistance development, and in-the-field artemisinin resistance development.

The data obtained here provide an attractive model linking DNA replication and artemisinin resistance; however, it is now important that this study is extended to include a larger number of clinical isolates from a wider geographic region. This would provide a better understanding on how the enhanced DNA repair phenotype is distributed in SEA and, more importantly, in Africa. Importantly, it would also provide us with a clearer picture on which genetic factors are more important for the phenotype and, therefore, make a more significant contribution. Ultimately, it will be necessary to experimentally validate these genetic associations and thereby definitively identify the critical mutations that underpin the DNA repair phenotype.

In conclusion, consistent with previous observations ([@bib34], [@bib35]; [@bib58]), the existence of parasites like KH44 indicated a founder population for drug resistance in the GMS with pre-deposing genetic factors, including mutations in DNA repair genes. Our study indicates that these mutations result in enhanced DNA repair that may enable parasites to tolerate more assaults on DNA; provide them with a higher survival chance; and, consequently, aids in the establishment and development of resistance. Future studies now need to further evaluate the importance of DNA damage repair in artemisinin resistance development, as this would, together with previous identified genetic factors ([@bib34], [@bib35]; [@bib58]), greatly aid in the identification and surveillance of areas that are particularly at risk to develop artemisinin resistance.
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Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Chemicals, Peptides, and Recombinant Proteins**RPMI medium 1640GIBCOCat\#31800089Sodium bicarbonateSigma-AldrichCat\#S5761HypoxanthineSigma-AldrichCat\#H9636GentamicinGIBCOCat\#15750060D-sorbitolSigma-AldrichCat\#S6021Giemsa stainSigma-AldrichCat\#GS500-500MLAlbuMAX™ II Lipid-Rich BSAGIBCOCat\#11021037Ferrous chlorideSigma-AldrichCat\#372870-25GFerric chloride hexahydrateSigma-AldrichCat\#236489-5GDeferoxamineSigma-AldrichCat\#D9533-1GAscorbic acidSigma-AldrichCat\#A92902-25GHeminSigma-AldrichCat\#51280-1GSodium hydroxideSigma-AldrichCat\#S5881-500GHydrogen peroxideMerckCat\#386790-100MLCNArtesunateSigma-AldrichCat\#A3731Low-melting point agaroseInvitrogen™Cat\#16520050Phosphate buffered salineLonzaCat\#17-516F (38210090)Sodium chlorideSigma-AldrichCat\#S3014Disodium EDTASigma-AldrichCat\#E5134Trizma® baseSigma-AldrichCat\#T1503Triton X-100Sigma-AldrichCat\#T8787Trizma® HClSigma-AldrichCat\#T3523SYBR GoldInvitrogen™Cat\#S11494Streptolysin OSigma-AldrichCat\#S5265-25KUDithiothreitolSigma-AldrichCat\#10197777001PercollSigma-AldrichCat\#P1644**Deposited Data**KH strains VCF filesWellcome Trust Sanger Institute, UKPf3K project release 5.1CometChip raw data and analyzed results, Part oneThis paper; Mendeley data<https://doi.org/10.17632/dfgj5ymxn7.1>CometChip raw data and analyzed results, Part twoThis paper; Mendeley data<https://doi.org/10.17632/sj6fsjpcmp.1>CometChip raw data and analyzed results, Part threeThis paper; Mendeley data<https://doi.org/10.17632/yncxdgwvs3.1>CometChip raw data and analyzed results, Part fourThis paper; Mendeley data<https://doi.org/10.17632/dwcv62mrbn.1>CometChip raw data and analyzed results, Part fiveThis paper; Mendeley data<https://doi.org/10.17632/8gsnzy5ndj.1>CometChip raw data and analyzed results, Part sixThis paper; Mendeley data<https://doi.org/10.17632/grdkg7rb83.1>**Experimental Models: Organisms/Strains**Plasmodium falciparum 3D7MR4N/APlasmodium falciparum Dd2 and Dd2^I543T^[@bib43]N/APlasmodium falciparum KH004 clinical isolates[@bib5]N/A**Recombinant DNA**Purified DNA: PlasmidAddgeneRRID: Addgene_128062**Software and Algorithms**ImageJ[@bib59]<https://imagej.nih.gov/ij/>MATLABThe MathWorks Inc.2018aGATK toolsBroad Institute, USA<https://gatk.broadinstitute.org/hc/en-us>vcftools[@bib12]<https://vcftools.github.io/index.html>SnpEff[@bib10]<http://snpeff.sourceforge.net/SnpEff.html>SNPhylo[@bib30]<https://github.com/thlee/SNPhylo>Guicometanalyzer[@bib54]<https://github.com/audreyx0206/MalariaCometChip>**Other**PDMS stamp[@bib54]N/AGelBond® filmLonzaCat\#53748; 110 mm x 205 mmBio-One™ 96-Well No Bottom MicroplatesGreinerCat\#07-000-626

Resource Availability {#sec4.2}
---------------------

### Lead Contact {#sec4.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Peter R. Preiser (<prpreiser@ntu.edu.sg>).

### Materials Availability {#sec4.2.2}

This study did not generate new unique reagents.

### Data and Code Availability {#sec4.2.3}

The Guicometanalyzer is available at <https://github.com/audreyx0206/MalariaCometChip> ([@bib54]). MalariaCometChip data generated and its related results are available at Mendeley data (DOI of Part I to VI: <https://doi.org/10.17632/dfgj5ymxn7.1>; <https://doi.org/10.17632/sj6fsjpcmp.1>; <https://doi.org/10.17632/yncxdgwvs3.1>; <https://doi.org/10.17632/8gsnzy5ndj.1>; <https://doi.org/10.17632/grdkg7rb83.1>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

*P. falciparum* strain 3D7 (MR4, USA) was cultured using fresh erythrocytes (Interstate Blood Bank, Inc) at 2.5% hematocrit in RPMI medium 1640 (GIBCO, USA) supplemented with 2.3 g/L sodium bicarbonate (Sigma-Aldrich, USA), 2.5 g/L AlbuMAX® (GIBCO, USA), 0.05 g/L of hypoxanthine (Sigma-Aldrich, USA) and 10 mg/L gentamicin (GIBCO, USA) (Noted as 'complete RPMI'). Complete RPMI without AlbuMAX® supplemented was noted as 'incomplete RPMI'. The parasites were incubated at 37°C with 5% CO~2~, 3% O~2~, and 92% N~2~. Parasites culture were regularly synchronized using 5% D-sorbitol (Sigma-Aldrich, USA). Parasitemia was quantified by standard Giemsa based microscopy. In Giemsa based microscopy, blood smears were fixed and permeabilized using 100% methanol and stained with 1X Giemsa stain (Sigma-Aldrich, USA). Parasitemia was then manually estimated at 1000X magnification using light microscope Olympus IX63.

Dd2 and Dd2^I543T^ were obtained from Prof. David Fidock (Columbia University, USA), which were generated in the study published as "K13-propeller mutations confer artemisinin resistance in *Plasmodium falciparum* clinical isolates" ([@bib43]). KH004 serial clinical isolates were obtained from Dr. Charles J. Woodrow (Mahidol Oxford Tropical Medicine Research Unit, Thailand and the Centre for Tropical Medicine, UK), which were collected from Cambodia for the clinical trial entitled "A multicenter, randomized trial to detect *in vivo* resistance of *Plasmodium falciparum* to artesunate in patients with uncomplicated malaria (TRAC Study)" ([@bib5]). These field isolates were independently culture-adapted as reported by Mukherjee et al., 2017 ([@bib37])., and all culture-adapted samples were confirmed to harbor monogenomic infections by molecular barcode analysis ([@bib37]). Cryo-preserved parasites were thawed using sorbitol gradient and cultured as described in previous section. Genotype information of the strains were obtained from Dr. Charles J. Woodrow and Prof. Olivo Miotto (Mahidol--Oxford Tropical Medicine Research Unit, Thailand and Nuffield Department of Medicine, the Medical Research Council Centre for Genomics and Global Health, University of Oxford and the Wellcome Trust Sanger Institute, Hinxton, UK).

Method Details {#sec4.4}
--------------

### Treatment of purified plasmid DNA with activated artesunate {#sec4.4.1}

Ferrous chloride (FeCl~2~), ferric chloride hexahydrate (FeCl~3~.~6~H~2~O), deferoxamine (DFO, an iron chelator) and ascorbic acid (Vitamin C \[Vc\], the activator of hemin) were solubilised in deionised water and hemin was solubilised in 0.1 M sodium hydroxide (NaOH) (all from Sigma-Aldrich, USA). A 30 μl reaction mix was prepared for each treatment buffered with 20 mM Tris-HCl, pH8.0. \~500 ng purified plasmid DNA (\~4 kb) was treated with different concentration of artesunate in presence and absence of 100 μM of ferric ion (FeCl~3~.~6~H~2~O), ferrous ion (FeCl~2~) and DFO. Similarly, in the second experimental set up, DNA was treated with varying concentration of artesunate in presence of 100 μM of hemin and Vc. DFO and Vc were added prior to the addition of artesunate in their respective tubes, and DNA was lastly added to the tubes. 1 mM hydrogen peroxide (H~2~O~2~) was used as positive control to treat the plasmid (7.6 kb). Reaction mixtures were incubated for different time points at 37°C. After completion of incubation, 20 μl samples were run on 0.8% agarose gel and analyzed.

### Fabrication of CometChip {#sec4.4.2}

CometChip assay was performed as described ([@bib54]; [@bib16], [@bib17], [@bib18]; [@bib46]; [@bib51]). A homemade PDMS stamp with an array of micropillars was obtained from Professor Bevin Engelward (Department of Biomedical Engineering, Massachusetts Institute of Technology, USA). Briefly, 1% w/v agarose (BioRad, USA) was dissolved in phosphate-buffered saline (PBS) (Lonza, USA) and applied to the hydrophilic side of GelBond® film (Lonza, USA). The PDMS stamp was pressed on top of the molten agarose gel to generate arrays of microwells with around 40-50 μm in both diameter and depth, 240 μm space. The agarose gel was allowed to solidify for 15 min before the stamp was removed. A bottomless 96-well plate was applied on top of the agarose gel chip and secured by clips to form 96 macrowells, with an array of \~300 microwells in each.

### Alkaline CometChip {#sec4.4.3}

For alkaline CometChip of *P. falciparum* parasites, 3% w/v agarose gel was used. Cell suspension was added to marcrowells of the chip and incubated at 37°C for 15 min in the incubator. Cells were captured in microwells by gravity and excess cells were washed off with PBS (Lonza, USA). After wash, the chip was overlaid with 1% w/v low-melting point agarose (ThermoFisher Scientific, USA) solution in PBS (melted and stabilized to 37°C before use). The chip was then kept at 4°C for 4 min for completely gelation of the overlaid agarose.

Alkaline lysis for the CometChip was performed at 4°C overnight. Alkaline lysis buffer (pH \~10) consisted of 2.5 M Sodium chloride, 100 mM disodium EDTA, 10 mM Trizma® base, and 1% v/v Triton X-100 (Sigma-Aldrich, USA) in deionized H~2~O. After alkaline lysis, the chip was submerged in cold alkaline electrophoresis buffer (pH \~13.5), containing 0.3 M sodium hydroxide and 1 mM disodium EDTA, to unwind the nuclei at 4°C for 40min. Electrophoresis was then performed in the same buffer at 4°C for 30 min at 1 V/cm and \~300 mA. The chip was washed twice at room temperature with neutralization buffer containing 0.4 M Trizma® HCl (Sigma-Aldrich, USA). The CometChip was stained with 1X of SYBR Gold (Invitrogen, USA) for 30 min at room temperature in dark. Fluorescent images of the comets were captured at 40X magnification using epifluorescence microscopes, Nikon Eclipse 80i or Olympus IX83, with a 480-nm excitation filter. A detailed video describing CometChip can be found in study done by Ge et al. ([@bib17]).

### Enrichment of live ring stage parasites using streptolysin O (SLO) {#sec4.4.4}

25,000 units of Streptolysin O (Sigma-Aldrich, USA) was dissolved in 2.25 mL PBS (Lonza, USA) and stored at −80°C as stock solution. 1 M dithiothreitol (DTT) (Sigma-Aldrich, USA) was prepared in deionized water and stored at −20°C. Hemolytic unit (HU) was determined as described ([@bib26]). SLO was activated by mixing 1 M DTT with SLO stock solution at 1:10 ratio and incubating at room temperature for 15 min. 20 μL of compact RBCs were lysed with different concentrations of activated SLO for 6 min, and centrifuged. Absorbance at 412 nm wavelength of the supernatant was measured by infinite M200 pro plate reader (Tecan, Switzerland). The 1 HU is defined as the amount of SLO required to cause 50% lysis of RBCs and was determined for each batch of SLO. Live ring stage parasites were enriched as described previously ([@bib23]). Briefly, 0 to 18 h.p.i. ring stage culture with more than 10% parasitemia was lysed with 4 HUs of activated SLO and washed with 1X PBS until the supernatant turned colorless. The enriched parasites were resuspended with complete RPMI for further experiments.

### Enrichment of schizont stage parasites using Percoll gradient {#sec4.4.5}

Parasites were synchronized at ring-stage (0-18 h.p.i) using 5% D-sorbitol and grow for another 30 h to achieve schizont stage. Schizont stage parasites (estimated 30-48 h.p.i) were purified using Percoll centrifugation as described ([@bib27]). Briefly, Percoll solution contains 63% Percoll (Sigma-Aldrich, USA), 27% 10X PBS and 10% incomplete RPMI. 1 mL parasite pellet were resuspended in 4ml incomplete RPMI. Resuspended parasites were gently layed on 10 mL Percoll gradient solution and underwent centrifugation at 2200 rpm, 11 min, brake 0. Schizont pellet were later recovered, washed with incomplete RPMI and proceed to further experiment.

### On-chip treatment using hydrogen peroxide {#sec4.4.6}

Parasites enriched using SLO lysis or percoll purification were resuspended in complete RPMI at 0.5% v/v. 100 ul cell suspension was added to each macro-well. After LMPA was laid onto the chip, a new bottomless 96-well plate was applied onto the chip. Hydrogen peroxide solution, stored at 4°C and protected from light, was diluted with cold PBS and kept on ice. Cells were treated with 100 ul of different concentrations of hydrogen peroxide for 20 min at 4°C. The chip was submerged to cold alkaline lysis buffer immediately after treatment.

### Off-chip treatment using artesunate {#sec4.4.7}

Artesunate (Sigma-Aldrich, USA) was dissolved to 50mM in 7.5% sodium bicarbonate solution (Sigma-Aldrich, USA). Aliquots of both were stored at −20°C and used one-time only without re-freezing. Parasites enriched using SLO lysis (0-18 h. p. i) or Percoll (30-48 h. p. i) purification were resuspended in complete RPMI at 0.5% v/v. 10X artesunate or mock solutions were prepared by diluting the stock with complete RPMI. Parasite suspension were incubated with different concentration of artesunate in 96-well plate for 1 h at 37°C. Treated parasites were transferred to CometChip by loading the parasite suspension into the macro-well of the CometChip using a multi-channel pipette and proceeded as describe previously. Drug is removed by washing the chip with 1X PBS. Each experiment was performed in technical triplicates and data shown were collected for biological triplicates.

### SNPs analysis {#sec4.4.8}

VCF files containing SNP information of various parasite strains were obtained from open source Pf3K project release 5.1 (Wellcome Trust Sanger Institute, UK), processed using GATK tools (Broad Institute, USA) and vcftools ([@bib12]), annotated using SnpEff ([@bib10]). Phylogenetic tree based on SNP profile was generated using SNPhylo ([@bib30]). Thank Prof. Arjen Dondorp for providing these samples, and MalariaGEN and Prof. Dominic Kwiatkowski group for sequencing and making the data available.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

MalariaCometChip images were analyzed using Guicometanalyzer, a customized software developed in MATLAB (The MathWorks Inc., USA) as described in detail in [Figure S2](#mmc1){ref-type="supplementary-material"} ([@bib54]; [@bib18]). Briefly, approximately 300 'comets' were generated in each well. The head and tail of the 'comet' are automatically recognized by the algorithm. The fluorescent intensity is recorded and used to calculate the relative proportion of DNA in the comet tail to the whole comet to obtain %Tail DNA. Same process is performed for each comet. Median of % tail DNA in each macro-well was then calculated from results generated in Guicometanalyzer. All experiments were performed in technical triplicates and data of biological triplicates were collected and shown in means ± SEM in this work. For artesunate and MMS treatment, data were normalized by keeping means of each CometChip in the biological triplicates same. One-way or two-way ANOVA were performed and significance (p value) was reported by Prism Graphpad 6. For experiments where *P. falciparum* 3D7 was treated with hydrogen peroxide and *P. falciparum* 3D7, Dd2 and Dd2^I543T^ were treated with artesunate, ordinary one-way ANOVA was used and Dunnett's multiple comparison tests were performed between vehicle control (0 μM) and respective concentrations. For Cambodian KH004 isolates treated with artesunate, two-way ANOVA was used, where comparisons were made between vehicle control and each concentration, and p values were adjusted after Šidák correction. Gene association were tested by Chi-square analysis and threshold of p value was adjusted after Bonferroni correction.
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